Navigating Preclinical Drug Development Challenges With Lipid-Based Formulations

Navigating preclinical drug development is inherently complex, often challenged by issues such as poor bioavailability of promising small-molecule candidates and constraints on time, cost, and available API. Nonclinical safety pharmacology and toxicology studies are critical steps on the path to first-in-human (FIH) trials, and for orally administered compounds, a central objective is maximizing API bioavailability to ensure a clear and accurate understanding of safety, exposure, and overall performance.

Lipid-based formulations (LBFs) offer a strategic solution to these challenges. Typically composed of lipids, surfactants, and/or cosolvents, LBFs are designed to enhance solubility and improve in vivo drug absorption. When applied in toxicology studies, they can significantly increase the bioavailability of difficult-to-formulate compounds while reducing API requirements and overall study costs. Importantly, well-designed LBF approaches can also support a smooth transition into clinical development, maintaining formulation continuity and minimizing redevelopment efforts.

Despite these advantages, LBFs remain underutilized — often due to perceived complexity and limited familiarity with how to effectively tailor these systems for success across development stages. This executive summary explores how to overcome these barriers, highlighting practical strategies to optimize the use of LBFs in both toxicology and clinical settings, and ultimately enabling more efficient, informed progression from preclinical studies to human trials.